Table 1.
Prevalence ratio of viral suppression a among patients retained on ART and with viral load measured – 10 health centres, Rwanda 2018 (N = 10,200)
| Total N | Virally suppressed, N (%) | PR (95% CI) | aPR (95% CI) | |
|---|---|---|---|---|
| Enrolment period | ||||
| 2000 to 2010 (referent) | 4826 | 4480 (93) | – | – |
| 2011 to 2013 | 2479 | 2279 (92) | 0.99 (0.97 to 1.01) | 0.99 (0.97 to 1.01) |
| 2014 to June 2016 | 1721 | 1536 (89) | 0.97 (0.95 to 0.98)* | 0.97 (0.95 to 0.99)* |
| July 2016 to 2017 (Treat All period) | 1174 | 1036 (88) | 0.95 (0.93 to 0.98)* | 0.98 (0.94 to 1.03) |
| Entry point into HIV care | ||||
| Routine HIV care and treatment programme (referent) | 9837 | 8996 (91) | – | – |
| PMTCT | 248 | 228 (92) | 1.01 (0.97 to 1.05) | 1.00 (0.95 to 1.05) |
| TB programme | 115 | 107 (93) | 1.02 (0.99 to 1.06) | 1.03 (1.00 to 1.05) |
| Sex | ||||
| Male (referent) | 4289 | 3898 (91) | – | – |
| Female | 5911 | 5433 (92) | 1.01 (1.00 to 1.03) | 1.01 (0.99 to 1.02) |
| Age in years (2018) | ||||
| >49 (referent) | 2478 | 2362 (95) | – | – |
| 25 to 49 | 6905 | 6310 (91) | 0.96 (0.94 to 0.98)* | 0.96 (0.95 to 0.98)* |
| 15 to 24 | 817 | 659 (81) | 0.84 (0.79 to 0.89)* | 0.83 (0.76 to 0.90)* |
| Most recent BMI (kg/m2) | ||||
| ≥18.5 (referent) | 6835 | 6307 (92) | – | – |
| <18.5 | 820 | 738 (90) | 0.98 (0.95 to 0.99)* | 0.99 (0.91 to 1.01) |
| Missing | 1000 | 918 (92) | 1.01 (0.96 to 1.06) | 1.00 (0.97 to 1.02) |
| Most recent WHO stage | ||||
| I or II (referent) | 8017 | 7358 (92) | – | – |
| III or IV | 1840 | 1663 (90) | 0.98 (0.97 to 1.00) | 0.99 (0.97 to 1.00) |
| Missing | 343 | 310 (90) | 0.99 (0.95 to 1.03) | 0.98 (0.91 to 1.05) |
| Pre‐ART CD4 count (cells/mm3) | ||||
| >500 (referent) | 2012 | 1889 (94) | – | – |
| 350 to 500 | 1509 | 1382 (92) | 0.98 (0.96 to 0.99)* | 0.97 (0.95 to 0.99)* |
| 200 to 349 | 2067 | 1900 (92) | 0.98 (0.97 to 0.99)* | 0.97 (0.96 to 0.98)* |
| <200 | 1245 | 1076 (86) | 0.92 (0.91 to 0.93)* | 0.92 (0.90 to 0.93)* |
| Missing | 2383 | 2198 (92) | 0.94 (0.92 to 0.96)* | 0.95 (0.94 to 0.97)* |
ART, antiretroviral therapy; BMI, body mass index; PMTCT, prevention of mother‐to‐child transmission; PR, prevalence ratio; TB, tuberculosis; WHO, World Health Organization.
a
< 200 copies/mL on last measured viral load during 2018.
*
p < 0.05.